ProKidney Corp.
PROK
Rank in Stocks
#13486
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase,... ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Share Price
$1.15
Last synced: 2026-11-09
Market Cap
$386.69M
Change (1 day)
0.88%
Change (1 year)
-58.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ProKidney Corp. (PROK)
Category
Healthcare
EPS for ProKidney Corp. (PROK)
EPS as of June 2026 TTM: $-0.57
According to ProKidney Corp.'s latest financial reports, its current EPS (TTM) is $-0.57. At the end of 2025 the company had an EPS of $-0.52, an increase over its 2024 EPS of $-0.62.
EPS history for ProKidney Corp. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.57 | 9.62% |
| 2025 | $-0.52 | -16.13% |
| 2024 | $-0.62 | 8.77% |
| 2023 | $-0.57 | -67.61% |
| 2022 | $-1.76 | 1.73% |
| 2021 | $-1.73 | 1,135.71% |
| 2020 | $-0.14 | -86.14% |
| 2019 | $-1.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,847.37% |
US
|
|
| $-7.07 | 1,140.35% |
US
|
|
| $-5.29 | 828.07% |
AU
|
|
| $12.88 | -2,359.67% |
BE
|
|
| $21.56 | -3,882.46% |
NL
|
Questions about ProKidney Corp.'s earnings per share (EPS)
What is ProKidney Corp.'s earnings per share (EPS)?
ProKidney Corp.'s earnings per share (EPS) over the last twelve months is $-0.57, as of Jun 2026.
What was ProKidney Corp.'s earnings per share (EPS) in 2025?
In 2025, ProKidney Corp.'s earnings per share (EPS) was $-0.52, compared with $-0.62 in 2024.
How has ProKidney Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, ProKidney Corp.'s earnings per share (EPS) was highest in 2020 ($-0.14) and lowest in 2022 ($-1.76).
How does ProKidney Corp.'s earnings per share (EPS) compare with similar companies?
ProKidney Corp.'s earnings per share (EPS) ($-0.57) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.